BLRX BioLineRx Ltd.
$2.51▼ -2.32%
Healthcare
Other
After hours
$2.51▲ +0.00%
Sep 11, 4:10 PM ET
Volume 9.5K
Avg Volume (10D) 44.8K
Key Metrics & Fundamentals
Market Cap
$12.17M
P/E Ratio
–
Div Yield
–%
52W Range
2.15 - 4.56
% vs 50 MA
-10.96%
% vs 200 MA
-13.03%
RSI-14
39.6
MACD Histogram
-0.0200
Beta (1Y vs SPY)
0.60
Free Cash Flow
-$3.21M
Gross Rev
$294,000
Gross Profit
$235,000
EBITDA
-$4.05M
COGS
$59,000
Operating Exp
$3.81M
Operating Income
-$3.57M
EBIT
-$3.57M
Pretax Income
-$4.34M
Net Income
-$3.03M
EPS (Diluted)
0.00
Price & Volume History
Loading chart…
Recent News
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
PR Newswire · Sep 10, 2026 11:00 AM
BLRX: New GLIX1 Data Touts Synergies
Zacks Small Cap Research · Sep 1, 2026 12:05 PM
BioLine Rx Ltd (BLRX) (Q2 2026) Earnings Call Highlights: Advancing GLIX1 Pipeline and ...
GuruFocus.com · Aug 31, 2026 9:00 PM
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
PR Newswire · Aug 31, 2026 11:00 AM
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement
PR Newswire · Aug 28, 2026 12:00 PM
BioLineRx to Report Second Quarter 2026 Results on August 31, 2026
PR Newswire · Aug 25, 2026 11:00 AM
BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026
PR Newswire · Jul 20, 2026 11:00 AM
BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model
PR Newswire · Jul 8, 2026 11:00 AM
Financial Overview - Income Statement
Quarterly
Jun 2026
See BLRX's money flow as a full page
Social Sentiment
No Reddit posts found for BLRX.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.